The World Health Organization cites multi-drug resistant (MDR) bacteria as one of the top three threats to human health. Unfortunately, antibiotic development has essentially ground to a halt thanks to these rapidly emerging resistant strains. No one wants to invest in a therapeutic with such a short shelf life. The need for a viable, broad treatment strategy is overwhelming. The only new classes of antibiotics introduced in the last twenty years are active solely against Gram-positive bacteria and resistance to these is already endemic. And that's the good news. Much worse, there have been no real advances in treating Gram- negative infections whatsoever. Clinicians have adopted the following mantra: """"""""for the treatment of Gram- positives we need better drugs;for Gram-negatives we need any drugs"""""""". Without a deeper understanding of the bacterial resistance/persistence and transmission mechanisms, along with the development of new approaches to combat these MDR pathogens, countless people will die. Our studies have two aims. First, we would like to better understand the protective mechanisms that bacteria employ to overcome antibiotics and the host immune response. Second, we would like to impede these mechanisms using small molecule intervention. During the last funding period we elucidated functional processes and molecular recognition characteristics of proteins involved in a variety of bacterial responses, including biofilm formation and environmental sensing. These studies were aimed at identifying 'druggable'points in signal transduction pathways. As a result of these efforts, we were able to develop an arsenal of compounds (referred to as 2AIs) that re-sensitize MDR bacteria (both Gram-positive and Gram-negative) to current antibiotics. We have demonstrated the efficacy of these compounds against 20-plus bacterial strains. Here we will characterize a complete signaling pathway responsible for biofilm matrix production in order to determine sites for possible therapeutic intervention, elucidate the mechanism of action of our 2AI compounds, develop improved 2AI compounds and evaluate lead 2AIs to act as adjuvants to current antibiotics in an animal model.
There is decreasing investment in antibiotic development because of the rapid increase in resistance to current antibiotics. It is not surprising that no on wants to develop new therapeutics that they believe will soon be useless. Such multi-drug resistance (MDR) will soon result in a worldwide infectious disease crisis. Here, we are addressing the MDR issue in two ways. First, by elucidating the detailed mechanisms by which pathogenic bacteria protect themselves - resulting in pathogenic infection, persistence and transmission. Second, by developing small molecule adjuvants that overcome these bacterial resistance traits such that MDR bacteria become susceptible to current antibiotics once again.
|Barker, William T; Martin, Sara E; Chandler, Courtney E et al. (2017) Small molecule adjuvants that suppress both chromosomal and mcr-1 encoded colistin-resistance and amplify colistin efficacy in polymyxin-susceptible bacteria. Bioorg Med Chem 25:5749-5753|
|Milton, Morgan E; Allen, C Leigh; Feldmann, Erik A et al. (2017) Structure of the Francisella response regulator QseB receiver domain, and characterization of QseB inhibition by antibiofilm 2-aminoimidazole-based compounds. Mol Microbiol 106:223-235|
|Stephens, Matthew D; Yodsanit, Nisakorn; Melander, Christian (2016) Evaluation of ethyl N-(2-phenethyl) carbamate analogues as biofilm inhibitors of methicillin resistant Staphylococcus aureus. Org Biomol Chem 14:6853-6|
|Stephens, Matthew D; Yodsanit, Nisakorn; Melander, Christian (2016) Potentiation of the Fosmidomycin analogue FR 900098 with substituted 2-oxazolines against Francisella novicida. Medchemcomm 7:1952-1956|
|Melander, Roberta J; Liu, Hong-Bing; Stephens, Matthew D et al. (2016) Marine sponge alkaloids as a source of anti-bacterial adjuvants. Bioorg Med Chem Lett 26:5863-5866|
|Stephens, Matthew D; Hubble, Veroncia B; Ernst, Robert K et al. (2016) Potentiation of Francisella Resistance to Conventional Antibiotics through Small Molecule Adjuvants. Medchemcomm 7:128-131|
|Brackett, Christopher M; Furlani, Robert E; Anderson, Ryan G et al. (2016) Second Generation Modifiers of Colistin Resistance Show Enhanced Activity and Lower Inherent Toxicity. Tetrahedron 72:3549-3553|
|Stowe, Sean D; Thompson, Richele J; Peng, Lingling et al. (2015) Membrane-permeabilizing activity of reverse-amide 2-aminoimidazole antibiofilm agents against Acinetobacter baumannii. Curr Drug Deliv 12:223-30|
|Tucker, Ashley T; Bobay, Benjamin G; Banse, Allison V et al. (2014) A DNA mimic: the structure and mechanism of action for the anti-repressor protein AbbA. J Mol Biol 426:1911-24|
|Melander, Roberta J; Minvielle, Marine J; Melander, Christian (2014) Controlling bacterial behavior with indole-containing natural products and derivatives. Tetrahedron 70:6363-6372|
Showing the most recent 10 out of 44 publications